Uncategorized
Ophthotech completes patient recruitment for third phase 3 trial of Fovista
Ophthotech has completed patient recruitment for a phase 3 clinical trial of Fovista in combination with anti-VEGF agents for the treatment of wet age-related macular degeneration, according to a press release.The three clinical trials in the phase 3 program are evaluating the safety and efficacy of Fovista (pegpleranib) in combination with anti-VEGF agents. The current third trial involves Fovista in combination with Eylea (aflibercept, Regeneron) or Avastin (bevacizumab, Genentech). The first two trials focused on Fovista in combination with Lucentis (ranibizumab, Genentech), and topline data are expected later this year.